We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 11 of 31 for:    O&O ALPAN

Safety Study of Replagal® Therapy in Children With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01363492
Recruitment Status : Completed
First Posted : June 1, 2011
Results First Posted : May 20, 2014
Last Update Posted : June 9, 2021
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:
The purpose of this study is to assess the safety of Replagal in children with Fabry disease who who have not previously been treated with enzyme replacement therapy (ERT).

Condition or disease Intervention/treatment Phase
Fabry Disease Biological: Replagal (agalsidase alfa) Phase 2

Detailed Description:

In 2008, a change in the agalsidase alfa drug substance manufacturing process was made. There are no changes to the drug product formulation, manufacturing site, manufacturing process, or container closure.

An agalsidase alfa bioreactor manufacturing process (agalAF1) utilizing animal component-free media replaced the previous roller bottle (RB) process.

This study will evaluate the safety of Replagal AF, manufactured using the new bioreactor process at a dose of 0.2 mg/kg infused IV over 40 minutes, every other week (EOW) in children with Fabry disease who are 7 years to less than 18 years of age and who are naive to ERT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy
Actual Study Start Date : May 12, 2011
Actual Primary Completion Date : April 17, 2013
Actual Study Completion Date : April 17, 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Replagal 0.2 mg/kg every other week (EOW) Biological: Replagal (agalsidase alfa)
0.2 mg/kg administered over 40 minutes every other week (EOW)
Other Name: agalsidase alfa

Primary Outcome Measures :
  1. Number of Serious Adverse Event (SAE) [ Time Frame: Baseline to week 55 ]
  2. Number of Treatment Emergent Adverse Event (TEAE) [ Time Frame: Baseline to week 55 ]
  3. Development of IgG Anti-Agalsidase Alfa Antibody [ Time Frame: Baseline to Week 55 ]
    Reflects development of Anti-Agalsidase antibodies post baseline

  4. Change From Baseline in Heart Rate Variability Parameter SDNN [ Time Frame: Baseline to week 55 ]
  5. Change From Baseline in Heart Rate Variability Parameter rMSSD [ Time Frame: Baseline to week 55 ]
  6. Change From Baseline in Heart Rate Variability Parameter pNN50 [ Time Frame: Baseline to week 55 ]

Secondary Outcome Measures :
  1. Change From Baseline in LVMI [ Time Frame: Baseline to week 55 ]
  2. Change From Baseline in MFS [ Time Frame: Baseline to week 55 ]
  3. Change From Baseline in Plasma Gb3 [ Time Frame: Baseline to week 55 ]
  4. Change From Baseline in Urine Gb3 [ Time Frame: Baseline to week 55 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   7 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must meet all of the following criteria to be enrolled in this study.

  1. All patients must be diagnosed with Fabry disease by the following criteria:

    • Male Patients: The patient is a hemizygous male with Fabry disease as confirmed by a deficiency of alfa-galactosidase A activity measured in serum, leukocytes, or fibroblasts or has a confirmed mutation of the alfa-galactosidase-A gene.
    • Female Patients: The patient is a heterozygous female with Fabry disease as confirmed by a mutation of the alfa-galactosidase A gene.

    Note: If the diagnosis of Fabry disease is previously documented in the patient's medical record, screening tests do not need to be repeated.

  2. The patient is 7 to <18 years of age
  3. The patient is ERT-naïve
  4. Adequate general health (as determined by the Investigators) to undergo the specified phlebotomy regimen and protocol-related procedures and no safety or medical contraindications for participation
  5. The minor child must assent to participate in the protocol and the parent(s) or legally authorized representative(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved informed consent form after all relevant aspects of the study have been explained and discussed with the child and the child's parent(s) or legally authorized representative(s)

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Patient and/or the patient's parent(s) or legally authorized representative(s) are unable to understand the nature, scope, and possible consequences of the study
  2. Patient is unable to comply with the protocol, eg, uncooperative with protocol schedule, refusal to agree to all of the study procedures, inability to return for evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator or the medical monitor.
  3. Otherwise unsuitable for the study, in the opinion of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01363492

Layout table for location information
United States, Georgia
Emory Division of Medical Genetics
Decatur, Georgia, United States, 30033
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
United States, Utah
University of Utah Hospital
Salt Lake City, Utah, United States, 84132
United States, Virginia
O & O Alpan LLC
Fairfax, Virginia, United States, 22152
Sponsors and Collaborators
Layout table for investigator information
Study Director: Study Director Takeda
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01363492    
Other Study ID Numbers: HGT-REP-084
First Posted: June 1, 2011    Key Record Dates
Results First Posted: May 20, 2014
Last Update Posted: June 9, 2021
Last Verified: May 2021
Keywords provided by Takeda ( Shire ):
agalsidase alfa
Enzyme Replacement Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders